ArticleMolecular cancer therapeutics2018

PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.

Fumi Higuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.